MN-MINNESOTA-RUBBER
Quadion LLC, d.b.a. Minnesota Rubber and Plastics (MRP), a leading provider of highly engineered elastomer and thermoplastic solutions for the medical, water and specialty industrial end markets, announced today its acquisition of Primasil Silicones Ltd. (Primasil), a Weobley, U.K.-based custom silicone rubber compounder, mixer and manufacturer specializing in the medical, HVAC and specialty industrial end markets.
“We're thrilled to add Primasil, a company with four decades of silicone materials science expertise, to our family. Primasil's custom material formulation, mixing and molding expertise will complement Minnesota Rubber and Plastic’s renowned materials science and molding capabilities. It will also provide a wide variety of new solutions for our clients," said Jay Ward, CEO of Minnesota Rubber and Plastics. "We have a long history of successfully serving our customers in Europe, and the addition of a highly technical production presence in the U.K. and Czech Republic will allow us to take our local capabilities to the next level. Not only will the acquisition augment our materials science and manufacturing capabilities, but it will also expand our global scope – particularly in the medical end market – and further our plans to expand our European footprint while we actively look to partner and acquire technical elastomer companies across the region."
Primasil offers a wide range of custom materials, including platinum-cured silicone, conductive silicone, flourosilicone, high- and low-temperature silicone, low smoke and toxicity silicone and black rubber. Primasil's proprietary silicone expertise will contribute to MRP's materials science-driven Innovation Center, launching Spring 2022. Furthermore, Primasil's high precision manufacturing capabilities include cleanroom molding, extrusion and assembly as well as mixing, injection molded and proprietary gum silicone and liquid silicone rubber (LSR) products.
The addition of Primasil's capabilities will complement MRP’s existing offerings, which include highly engineered elastomer and thermoplastic solutions for the medical device, water, food and beverage, infrastructure and other essential industries globally. MRP built its strong reputation over its more than 75-year history for designing, developing, manufacturing and assembling products for harsh environments, tight tolerances and technically demanding applications, including multi-material solutions and custom material formulations.
"The Primasil team is extremely excited about this opportunity. We look forward to working alongside our new colleagues at Minnesota Rubber and Plastics to continue serving our valued customers – in Europe and around the globe – with innovative technologies, great talent and more options than ever before," said Steve Wheeler, Managing Director of Primasil. "We're not just acquiring great products and capabilities to complement our current offerings; we're adding a world-class team. We plan to extend ownership to all of the new colleagues we welcome onboard from Primasil," added Ward.
Wheeler will continue to lead Primasil, reporting into the MRP organization. For more information about Minnesota Rubber and Plastics and its current offerings, visit www.mnrubber.com .
About Primasil Silicones
Primasil was founded in 1978 to meet growing needs for silicone rubber. Originally a moulding company, Primasil soon expanded to offer extrusion and develop their own custom formulations, quickly becoming the leading independent U.K. supplier of silicone rubber compounds. Today, Primasil continues to supply silicone products and materials all over the world to a variety of industries, including aerospace, automotive, electronics, medical and pharmaceutical and rail and mass transit. For more information, please visit www.primasil.com
.
About Minnesota Rubber and Plastics
Minnesota Rubber and Plastics (MRP) is a leader in material compound development and the manufacturing of custom elastomeric and thermoplastic components. For 77 years, the company has built a reputation for collaborative design and successful production of “the tough parts.” With facilities across North America, Europe and Asia, MRP collaborates with original equipment manufacturers to solve difficult sealing and component challenges across multiple markets. Capabilities include materials science and formulation, fully functional product prototyping and operational excellence and supply chain consolidation. The company’s Innovation Center, coming spring of 2022, will provide its customers with enhanced direct access to materials science expertise and a fully integrated design-build-prototype-test process that enhances innovation and greatly accelerates product development. The company places emphasis on research and development and empowers its technicians to design, formulate, develop and test a wide range of highly engineered materials and parts. For more information, please visit www.mnrubber.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220307005192/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom